9 April 2021
Appendix 2A
30 March 2021
VIRALEZE™ now launched by LloydsPharmacy in the UK
25 March 2021
VIRALEZE™ to be launched with LloydsPharmacy in the UK
16 March 2021
DEP® HER2-lutetium outperforms in human breast cancer model
3 March 2021
SPL7013 active against other pandemic coronaviruses
25 February 2021
Interim Report and Half-Year Financial Results
23 February 2021
VIRALEZE™ antiviral nasal spray registered in Europe
12 February 2021
Starpharma signs DEP® ADC Research Agreement with MSD
9 February 2021
AZD0466 clinical DEP® program global expansion
3 February 2021
Change in substantial holding
29 January 2021
Quarterly Cashflow and Activities Report
27 January 2021
Appendix 2A
18 January 2021
Change in substantial holding
18 January 2021
Change in substantial holding
24 December 2020
Change in substantial holding
22 December 2020
VIRALEZE COVID-19 nasal spray study to commence in January
22 December 2020
Change in substantial holding
10 December 2020
VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21
24 November 2020
Change in Director's Interest Notice - J Fairley
24 November 2020
Appendix 3G

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com


This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.